AtriCure, Inc. (ATRC)
NASDAQ: ATRC · Real-Time Price · USD
41.04
-1.34 (-3.16%)
Dec 15, 2025, 4:00 PM EST - Market closed
AtriCure Revenue
AtriCure had revenue of $134.27M in the quarter ending September 30, 2025, with 15.84% growth. This brings the company's revenue in the last twelve months to $518.31M, up 15.80% year-over-year. In the year 2024, AtriCure had annual revenue of $465.31M with 16.55% growth.
Revenue (ttm)
$518.31M
Revenue Growth
+15.80%
P/S Ratio
3.76
Revenue / Employee
$398,696
Employees
1,300
Market Cap
2.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 465.31M | 66.06M | 16.55% |
| Dec 31, 2023 | 399.25M | 68.87M | 20.84% |
| Dec 31, 2022 | 330.38M | 56.05M | 20.43% |
| Dec 31, 2021 | 274.33M | 67.80M | 32.83% |
| Dec 31, 2020 | 206.53M | -24.28M | -10.52% |
| Dec 31, 2019 | 230.81M | 29.18M | 14.47% |
| Dec 31, 2018 | 201.63M | 26.91M | 15.40% |
| Dec 31, 2017 | 174.72M | 19.61M | 12.64% |
| Dec 31, 2016 | 155.11M | 25.35M | 19.54% |
| Dec 31, 2015 | 129.76M | 22.30M | 20.75% |
| Dec 31, 2014 | 107.45M | 25.57M | 31.22% |
| Dec 31, 2013 | 81.89M | 11.64M | 16.57% |
| Dec 31, 2012 | 70.25M | 5.85M | 9.08% |
| Dec 31, 2011 | 64.40M | 5.40M | 9.14% |
| Dec 31, 2010 | 59.01M | 4.47M | 8.20% |
| Dec 31, 2009 | 54.53M | -723.47K | -1.31% |
| Dec 31, 2008 | 55.26M | 6.95M | 14.38% |
| Dec 31, 2007 | 48.31M | 10.07M | 26.32% |
| Dec 31, 2006 | 38.24M | 7.29M | 23.54% |
| Dec 31, 2005 | 30.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ATRC News
- 4 days ago - AtriCure Announces the First Patients Treated with Novel Dual Energy Platform - Business Wire
- 16 days ago - Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares? - The Motley Fool
- 27 days ago - AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 5 weeks ago - AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 weeks ago - AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025 - Business Wire
- 7 weeks ago - AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial - Business Wire
- 7 weeks ago - AtriCure to Participate in Upcoming Investor Conferences - Business Wire